Alzheimer’s drug development could be aided by multiple mouse-model validation Research suggests that GPR3, a receptor implicated in Alzheimer’s disease pathology, mediates disease progression and is a potential target for drug development.…
Volunteers are vital to tackling dementia As research into dementia grows, so does the demand for research volunteers.…
Brains of CJD victims show signs of Alzheimer’s pathology Victims of Creutzfeldt–Jakob disease show evidence of Alzheimer’s pathology, suggests new research. But neuroscientists have quashed fears that people can “catch” Alzheimer’s.…
2015 RPS award winners announced The winners of this year’s Royal Pharmaceutical Society Awards were revealed at the annual conference in Birmingham on 13 September 2015.…
Widespread prescribing of antipsychotics for intellectually disabled people revealed As many as 71% of adults with a learning disability were prescribed an antipsychotic when they had no record of any mental illness, a study reported in The BMJ has found.…
Omega-3 supplements fail to slow cognitive decline Using supplements of omega-3 fatty acids or other nutrients found in green leafy vegetables does not slow down cognitive decline in older people, according to new research.…
Benefits of insulin in Alzheimer’s disease analysed in mouse study Researchers study mice to determine how insulin can improve symptoms of Alzheimer’s disease.…
Closing in on Alzheimer’s disease Knowledge about the neuropathology of Alzheimer’s disease has blossomed over the past few decades, leading to a better understanding of the condition and new ways to attack it.…
Data suggest that new Alzheimer’s drug solanezumab has disease-modifying properties A monoclonal antibody in development for the treatment of Alzheimer’s disease (AD) may have disease-modifying properties, according to new research.…
Clinical Pharmacist’s monthly news round-up: the top 10 in the past month What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month.…
